Myrtle Potter Sells 1,556 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Myrtle Potter sold 1,556 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $204,084.96. Following the sale, the director directly owned 20,971 shares in the company, valued at $2,750,556.36. This trade represents a 6.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Stock Up 4.7%

GH stock opened at $136.96 on Thursday. The firm has a market capitalization of $18.16 billion, a PE ratio of -40.40 and a beta of 1.61. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $141.07. The stock has a 50-day simple moving average of $110.21 and a two-hundred day simple moving average of $103.42.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently bought and sold shares of GH. Vanguard Group Inc. lifted its position in Guardant Health by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after acquiring an additional 435,232 shares during the last quarter. Geode Capital Management LLC grew its position in Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after acquiring an additional 277,001 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its stake in Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after acquiring an additional 72,162 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GH. The Goldman Sachs Group started coverage on shares of Guardant Health in a research note on Friday, June 5th. They set a “buy” rating and a $165.00 price objective for the company. Wolfe Research assumed coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 target price on the stock. Evercore upgraded shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price target for the company in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Finally, Piper Sandler set a $127.00 price objective on Guardant Health in a research report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $142.19.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.